Articles tagged with Antagonists
A large study on very old patients with atrial fibrillation found that adequate management of anticoagulation therapy can reduce bleeding risks. The study suggests that age should not be a contraindication to treatment for these patients.
A Cochrane Systematic Review revises conclusions on two fertility treatments, finding GnRH antagonists comparable to agonists in live birth rates while reducing ovarian hyperstimulation syndrome risks. This shift justifies the use of GnRH antagonists over agonists.
A systematic review found that one in every 200 inpatients taking acid suppressive medications developed pneumonia. The study suggests that deaths from hospital-acquired pneumonia could be caused by these medications.
A CXCR4 antagonist, AMD3100, decreases epithelial apoptosis and gut permeability in experimental colitis, enhancing epithelial barrier function. This study suggests a pivotal role of the CXCL12/CXCR4 chemokine axis in ulcerative colitis pathogenesis.
A Scripps Research Institute team discovered corticotropin-releasing factor (CRF) plays a crucial role in alcohol dependence. Blocking CRF with antagonists blocked addiction symptoms and increased sensitivity to treatment, suggesting a new approach for substance abuse treatment.
A study of over 40,000 Danish patients found that those taking more than one anti-bleeding medication after a heart attack were at higher risk of non-fatal and fatal bleeding. Non-fatal bleeding was also associated with an increased risk of repeat heart attacks or death.
A study found that only one-third of US patients meeting guidelines criteria were treated with aldosterone antagonists, compared to 48% in the Euro Heart Failure survey. European clinicians have greater leeway and often push new indications in their practice, leading to a more liberal approach.
Recent data suggests that less than one-third of hospitalized heart failure patients received guideline-recommended aldosterone antagonist therapy. The study analyzed hospital-based quality improvement registry data and found modest increases in treatment use over time, but significant variation among hospitals.
A study of 84,832 babies found that folic acid antagonists in early pregnancy more than doubled the risk of congenital malformations. Neural tube defects, such as spina bifida, increased by six-fold after exposure to these medications.
The International Conference on Endothelin presented promising results for new endothelin receptor antagonist drugs, which may benefit conditions like kidney disease and pulmonary hypertension. However, challenges in determining the best treatment approach and addressing potential side effects must be overcome.
Researchers have identified new folate antagonists that selectively target activated macrophages in the joints of RA patients. These agents show high binding affinity for folate receptor β, a highly specific pathway involved in rheumatoid arthritis.
A phase III trial found that palonosetron was non-inferior to granisetron in preventing acute nausea and vomiting but more effective in the delayed phase, offering a safer alternative for chemotherapy prevention.
A retrospective cohort study found maternal exposure to folic acid antagonists during pregnancy increases the risk of adverse outcomes such as preeclampsia and fetal growth restriction. The study recommends re-classifying some folic acid antagonists and increasing folic acid supplements for women taking these medications during pregnancy.
A new study suggests that blocking the corticotrophin releasing factor-1 (CRF1) receptor and the vasopressin-1B (V1B) receptor may retain their efficacy in treating depression, even when neurogenesis is disrupted. The researchers found that restoration of the stress axis may be key to how these new antidepressant approaches work.
A trial found idraparinux causes significantly more bleeding than vitamin K antagonists in patients with atrial fibrillation at risk of stroke. The treatment requires regular monitoring and dose adjustment, but an unmonitored regimen would be preferable for improved safety.
New compounds that target Inhibitor-of-Apoptosis (IAP) proteins have been shown to induce apoptosis in tumor cells. The IAP antagonists block the anti-death proteins and engage other players that lead to cell death, with little effect on healthy cells.
A novel platelet therapy, SCH 530348, has demonstrated safety and efficacy in reducing percutaneous coronary intervention (PCI) complications. Major adverse events were reduced by 1.6-3.5% in low-dose cohorts compared to placebo. The treatment also showed a lower risk of death or major adverse events and heart attack compared to placebo.
Researchers at Salk Institute and collaborators found that antagonists, not agonists, are more effective in targeting tumors. Antagonists can bind to a greater variety of receptor conformations, making them a more efficient target.
The ISAR-REACT 2 Trial found that abciximab significantly reduced the risk of death, heart attack, and ischemic complications in patients with non-ST-segment elevation ACS undergoing PCI. The study also showed no significant difference in bleeding risks between the two groups.
A new class of drug has been shown to reduce post-operative vomiting in 95% of patients, with no significant difference in nausea reduction compared to existing anti-emetic drugs. The NK-1 receptor antagonist was found to be well-tolerated and effective in preventing vomiting after surgery.
GSK researchers have developed non-peptide selective oxytocin receptor antagonists with high affinity for human and rat OT receptors, suppressing myometrial contractions and potentially delaying labor. These compounds may significantly reduce infant morbidity, including lung disease, intraventricular hemorrhage, and death.
A Phase IIa study found that patients given clazosentan suffered from significantly fewer and less severe cases of cerebral vasospasm compared to placebo. The treatment was also associated with a lower incidence of new cerebral infarcts.
The study found that Twist1 and Hand2 proteins couple to determine the number of digits on a hand, paw or wing, and whether these digits are webbed or not. Additionally, the researchers identified high-frequency mutations in patients with Saethre-Chotzen Syndrome, which may lead to cardiac and placental tissue defects.
EMSELEX, a new drug for treating overactive bladder, has shown efficacy in reducing incontinence episodes by up to 77% compared to placebo. The medication, selective for the M3 receptor, also improves symptoms such as urinary frequency and urgency.
New research suggests a link between galanin and alcohol consumption, as well as its effects on food intake. Galanin was found to increase voluntary alcohol intake in rodents, but not food intake. A galanin receptor antagonist also reduced alcohol drinking, suggesting a potential role for these compounds in treating alcohol dependence.
Emselex(R) has been proven to improve overactive bladder (OAB) symptoms without causing significant adverse events. The treatment has shown efficacy in reducing urinary urgency and urge incontinence, making it a promising new option for patients.
A multicentre study found that darifenacin significantly improved median warning time by 4.3 minutes in patients with overactive bladder syndrome, leading to a 22.5% increase in mean warning time.
Researchers found that sigma receptor antagonists reduced toxic and stimulant effects of cocaine in mice, indicating a possible link between sigma receptors and cocaine's actions. Antisense oligodeoxynucleotides also showed promise in reducing cocaine's effects by decreasing sigma receptor numbers.
Researchers at Max Planck Institute of Experimental Medicine discovered a molecular switch in CRF by replacing a single amino acid, allowing for the development of selective CRF-like agonists and antagonists. This breakthrough has potential applications in treating anxiety disorders.
Researchers investigated bosentan's effectiveness in treating patients with severe pulmonary hypertension. Bosentan improved cardiopulmonary haemodynamics and reduced pulmonary artery pressure in patients compared to placebo.
Researchers at Yale Cancer Center identified two mechanisms to inhibit the Survivin gene's protective function, which can lead to cancer cell death. The study used molecular antagonists and showed promise in preclinical studies, paving the way for potential therapeutic applications.
A new study at Ohio University found that growth hormone is important in the development of Type I diabetes-induced kidney damage. The researchers induced Type I diabetes in mice and found that those with disrupted growth hormone receptors did not develop diabetic kidney disease.
A study found that individuals taking nisoldipine had a higher rate of fatal and non-fatal heart attacks compared to those taking enalapril, sparking concerns about the safety of calcium antagonists for certain populations. The American Heart Association advises against panic and emphasizes the need for consultation with physicians.
Researchers discovered a growth hormone antagonist that reduces eye disease by 33-44% in mice. The findings suggest the use of this antagonist or a drug inhibiting growth hormone release may help prevent retinal neovascularization and treat related eye diseases.